Davide Campobasso1, Michele Marchioni2, Vincenzo Altieri3, Francesco Greco3, Cosimo De Nunzio4, Paolo Destefanis5, Stefano Ricciardulli6, Franco Bergamaschi6, Giuseppe Fasolis7, Francesco Varvello7, Salvatore Voce8, Fabiano Palmieri8, Claudio Divan9, Gianni Malossini9, Rino Oriti10, Agostino Tuccio11, Lorenzo Ruggera12, Andrea Tubaro4, Giampaolo Delicato13, Antonino Laganà13, Claudio Dadone14, Gaetano De Rienzo15, Antonio Frattini1, Lugi Pucci16, Maurizio Carrino16, Franco Montefiore17, Stefano Germani18, Roberto Miano19, Luigi Schips20, Salvatore Rabito21, Giovanni Ferrari21, Luca Cindolo22. 1. Department of Urology, Ospedale Civile di Guastalla and Ospedale Ercole Franchini di Montecchio Emilia, Azienda USL-IRCCS di Reggio Emilia, Guastalla, Italy. 2. Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University of Chieti, Chieti, Italy. 3. Department of Urology, Humanitas Gavazzeni, Bergamo, Italy. 4. Department of Urology, "Sant'Andrea" Hospital, Sapienza University, Roma, Italy. 5. Department of Urology, Azienda Ospedaliera Città della Salute e della Scienza di Torino-Sede Molinette, Torino, Italy. 6. Department of Urology, "Arcispedale Santa Maria Nuova," Reggio Emilia, Italy. 7. Department of Urology, "S. Lazzaro" Hospital, Alba, Italy. 8. Department of Urology, "Santa Maria delle Croci Hospital," Ravenna, Italy. 9. Department of Urology, "Rovereto Hospital," Rovereto, Italy. 10. Department of Urology, "Ulivella e Glicini Clinic," Florence, Italy. 11. Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy. 12. Department of Urology, Clinica urologica azienda ospedaliera, University of Padova, Padova, Italy. 13. Department of Urology, "S. Giovanni Evangelista" Hospital, Tivoli, Italy. 14. Department of Urology, "Santa Croce e Carle" Hospital, Cuneo, Italy. 15. Department of Emergency and Organ Transplantation, Urology and Andrology Unit II, University of Bari, Bari, Italy. 16. Department of Urology, AORN "Antonio Cardarelli," Naples, Italy. 17. Department of Urology, "San Giacomo" Hospital, Novi Ligure, Italy. 18. UOSD Urologia, Fondazione Policlinico Tor Vergata, Rome, Italy. 19. UOSD Urologia, Dipartimento di Scienze Chirurgiche, Fondazione Policlinico Tor Vergata, Università di Roma Tor Vergata, Rome, Italy. 20. Department of Urology, ASL Abruzzo 2, Chieti, Italy. 21. Department of Urology, "Hesperia Hospital," Modena, Italy. 22. Department of Urology, "Villa Stuart" Private Hospital, Rome, Italy.
Abstract
Introduction: GreenLight laser vaporization of the prostate (photoselective vaporization of the prostate [PVP]) is a safe and effective procedure for Benign Prostatic Hyperplasia. Long-term results and advantages of PVP in patients with large and symptomatic prostate are still under evaluation. Materials and Methods: In a multicenter experience, patients who underwent standard or anatomical PVP were retrospectively reviewed. Patients with follow-up >12 months were divided into two groups based on prostate volume (<100 cc vs ≥100 cc). Pre- and perioperative data, as well as postoperative results and complications, were recorded after 3, 6, and 12 months and then annually. Results: One thousand and thirty-one patients were eligible, 916 of these had a prostate volume of <100 cc and 115 ≥ 100 cc. Median follow-up period was 25.0 months (interquartile range [IQR] 16.5-35.0) and 16.0 months (IQR 12.0-24.0) in ≥100 and <100 groups, respectively. No difference was found in terms of catheterization time, postoperative stay, and postoperative acute urine retention. Patients with prostate ≥100 required longer operative time (75 vs 55 minutes), lasing time (41.7 vs 24.9 minutes), and higher energy used but lower energy density. Patients with prostate ≥100 had a higher incidence of early (50.4% vs 35.7%) and late complications (21.7% vs 12.8%) and early urge/incontinence symptoms (40.9% vs 29.3%). No statistically significant differences were found for the maximum urinary flow (Qmax) and International Prostate Symptom Score (IPSS) results between the two groups. The reintervention rate in ≥100 group was 3.5% vs 2.3% in <100. Conclusions: In the midterm follow-up, GreenLight PVP guarantees the same results in different prostate volume groups. Early and late complications are more frequent in large prostates.
Introduction: GreenLight laser vaporization of the prostate (photoselective vaporization of the prostate [PVP]) is a safe and effective procedure for Benign Prostatic Hyperplasia. Long-term results and advantages of PVP in patients with large and symptomatic prostate are still under evaluation. Materials and Methods: In a multicenter experience, patients who underwent standard or anatomical PVP were retrospectively reviewed. Patients with follow-up >12 months were divided into two groups based on prostate volume (<100 cc vs ≥100 cc). Pre- and perioperative data, as well as postoperative results and complications, were recorded after 3, 6, and 12 months and then annually. Results: One thousand and thirty-one patients were eligible, 916 of these had a prostate volume of <100 cc and 115 ≥ 100 cc. Median follow-up period was 25.0 months (interquartile range [IQR] 16.5-35.0) and 16.0 months (IQR 12.0-24.0) in ≥100 and <100 groups, respectively. No difference was found in terms of catheterization time, postoperative stay, and postoperative acute urine retention. Patients with prostate ≥100 required longer operative time (75 vs 55 minutes), lasing time (41.7 vs 24.9 minutes), and higher energy used but lower energy density. Patients with prostate ≥100 had a higher incidence of early (50.4% vs 35.7%) and late complications (21.7% vs 12.8%) and early urge/incontinence symptoms (40.9% vs 29.3%). No statistically significant differences were found for the maximum urinary flow (Qmax) and International Prostate Symptom Score (IPSS) results between the two groups. The reintervention rate in ≥100 group was 3.5% vs 2.3% in <100. Conclusions: In the midterm follow-up, GreenLight PVP guarantees the same results in different prostate volume groups. Early and late complications are more frequent in large prostates.
Entities:
Keywords:
GreenLight; XPS; large prostate; outcomes; photoselective vaporization of the prostate
Authors: Russell N Schwartz; Felix Couture; Iman Sadri; Adel Arezki; David-Dan Nguyen; Ahmed S Zakaria; Kyle Law; Dean Elterman; Malte Rieken; Hannes Cash; Kevin C Zorn Journal: World J Urol Date: 2020-09-15 Impact factor: 4.226
Authors: Kyle W Law; Côme Tholomier; David-Dan Nguyen; Iman Sadri; Félix Couture; Ahmed S Zakaria; David Bouhadana; Franck Bruyère; Hannes Cash; Maximilian Reimann; Luca Cindolo; Giovanni Ferrari; Carlos Vasquez-Lastra; Tiago J Borelli-Bovo; Edgardo F Becher; Vincent Misrai; Dean Elterman; Naeem Bhojani; Kevin C Zorn Journal: World J Urol Date: 2021-04-10 Impact factor: 4.226